ITEOS THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
ITEOS THERAPEUTICS INC. - More news...
ITEOS THERAPEUTICS INC. - More news...
- iTeos to Participate in Upcoming Investor Conferences
- iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates
- iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress
- iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
- iTeos to Participate in Upcoming Investor Conferences
- iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024
- iTeos Reports Second Quarter 2024 Financial Results and Provides Business Updates
- iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer
- iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK
- iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer
- iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates
- iTeos Therapeutics Announces $120 Million Registered Direct Offering
- iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024
- iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors
- iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
- iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024
- iTeos to Participate in Upcoming Investor Conferences
- iTeos Announces 2024 Strategic Priorities and Anticipated Milestones
- iTeos to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference
- iTeos Reports Third Quarter 2023 Financial Results and Provides Business Updates
- iTeos to Participate in Upcoming Investor Conferences
- iTeos Reports Second Quarter 2023 Financial Results and Provides Business Updates
- iTeos Reports First Quarter 2023 Financial Results and Provides Business Updates
- iTeos Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
- iTeos to Present at SVB Securities Global Biopharma Conference
- iTeos Provides Business Updates and Clinical Development Plans for 2023
- iTeos to Present at the 41st Annual J.P. Morgan Healthcare Conference
- iTeos to Present at the Piper Sandler 34th Annual Healthcare Conference
- iTeos Reports Third Quarter 2022 Financial Results and Provides Business Updates
